The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...